sofosbuvir has been researched along with 2019 Novel Coronavirus Disease in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 25 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belal, F; El-Shorbagy, HI | 1 |
| Abbaspour Kasgari, H; Abdollahi, M; Abedi, F; Afshari, M; Akbarpour, E; Ali Asgari, A; Anushiravani, A; Arizavi, Z; Azarkar, Z; Azimi, E; Babamahmoodi, F; Bahadori, AR; Barahimi, E; Bonyadi, A; Davoodi, L; Davoudi Badabi, AR; Dehghan Manshadi, SA; Dehghani, F; Ebrahimzadeh, A; Ebrahimzadeh, M; Eslami, G; Esmaeilian, H; Fakheri, H; Hasooni Bahrini, N; Hassaniazad, M; Hill, A; Hormati, A; Hosamirudsari, H; Jelvay, S; Joukar, F; Karimi, J; Khajavirad, N; Khodadadi, J; Levi, J; Mansour-Ghanaei, F; McCann, K; Mehrabi, Z; Merat, D; Merat, S; Mirzaei, H; Mobarak, M; Mobarak, S; Moghimi, M; Moslemi, R; Mousavi, H; Mousaviasl, S; Naghipour, M; Nateghi Baygi, A; Nateghi Baygi, H; Nekoukar, Z; Noori Jangi, M; Poormontaseri, Z; Pourmasoomi, H; Radmanesh, E; Rezaie Keikhaie, L; Sadeghi, A; Salasi, M; Salehi, M; Salmanzadeh, S; Sayar, S; Shabani, AM; Shabani, M; Shokouhi, S; Simmons, B; Tousi, A; Wentzel, H; Yaghoubi, S; Yaghubi Kalurazi, T; Yeganeh, S; Zeinali, A; Ziaee, M; Zolfaghari, F | 1 |
| Abdelazim, AH; Ramzy, S | 1 |
| Chanihoon, GQ; Jafar, TH; Khalid, Z; Maneengam, A; Mangrio, GR; Nassani, R; Unar, A | 1 |
| Akpomiemie, G; Bosch, B; Casas, CP; Ellis, L; Hill, A; Johnstone, H; Owen, A; Simmons, B; Sokhela, S; Venter, WDF; Woods, J | 1 |
| Bearne, SL; Gillis, TD | 1 |
| Pranata, R; Raffaello, WM; Sulistiyana, CS; Wibowo, A; Zein, AFMZ | 1 |
| Elfiky, AA | 1 |
| Khodarahmi, R; Sayad, B; Sobhani, M | 1 |
| Khalili, H; Nourian, A | 1 |
| Izzi, A; Maggi, P; Messina, V; Rinaldi, L | 1 |
| Becerra, A; Campillo-Balderas, JA; Jácome, R; Lazcano, A; Ponce de León, S | 1 |
| Anderson, TK; Chien, M; Jockusch, S; Ju, J; Kirchdoerfer, RN; Kumar, S; Li, X; Russo, JJ; Tao, C | 1 |
| Abbaspour Kasgari, H; Alikhani, A; Babamahmoodi, F; Davoudi Badabi, AR; Davoudi, L; Garratt, A; Hedayatizadeh Omran, A; Hill, A; Levi, J; Merat, S; Moradi, S; Saeedi, M; Shabani, AM; Simmons, B; Tirgar Fakheri, H; Wentzel, H | 1 |
| Afhami, S; Akbarpour, E; Ali Asgari, A; Aliannejad, R; Anushirvani, A; Davarpanah, AH; Garratt, A; Hill, A; Hosamirudsai, H; Kheiri, Z; Levi, J; Merat, S; Montazeri, M; Norouzi, A; Qavi, A; Radmard, AR; Sadeghi, A; Simmons, B; Wentzel, H | 1 |
| Bitaraf, S; Eslami, G; Esmaeilian, H; Freeman, J; Hajizadeh Farsani, M; Hill, A; Jafari Kashi, AH; Jelvay, S; Lotfi, Z; Marjani, S; Mobarak, M; Mobarak, S; Momtazan, M; Mousaviasl, S; Radmanesh, E; Sadeghi, A; Salmanzadeh, S; Simmons, B; Tabibi, R; Talebzadeh, SM; Wentzel, H; Wickramatillake, A | 1 |
| Perišić, O | 1 |
| Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C | 1 |
| Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kirchdoerfer, RN; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C | 1 |
| Chen, S; Song, W; Yi, Z; Yuan, Z; Zhang, Y | 1 |
| Alizadeh-Navaei, R; Hedayatizadeh-Omran, A; Hill, A; Levi, J; Merat, S; Roozbeh, F; Saeedi, M; Shamshirian, A; Wentzel, H | 1 |
| Chan, HT; Chao, CM; Lai, CC | 1 |
| Bastos, MM; Boechat, N; Bou-Habib, DC; Bozza, FA; Bozza, PT; Branco, FSC; Chien, M; Da Silva, APD; da Silva, CDS; de Freitas, CS; Dias, SDSG; Fernandes, TVA; Ferreira, AC; Ferreira, MA; Fintelman-Rodrigues, N; Garzia, A; Goto-Silva, L; Guimarães, MZ; Hoelz, LVB; Jockusch, S; Ju, J; Mattos, M; Owen, A; Pão, CRR; Patel, D; Pedrosa, CSG; Rajoli, RKR; Rehen, SK; Russo, JJ; Sacramento, CQ; Saraiva, FB; Soares, VC; Souza, LRQ; Souza, TML; Tao, C; Temerozo, JR; Tuschl, T; Vitória, G; Wang, X; Xie, W | 1 |
| Afsharian, M; Bozorgomid, A; Janbakhsh, A; Khodarahmi, R; Khosravi Shadmani, F; Mansouri, F; Miladi, R; Mohseni Afshar, Z; Najafi, F; Rahimi, Z; Salimi, M; Sayad, B; Shirvani, M; Vaziri, S; Zamanian, MH | 1 |
| Abd Elghafar, M; Abd-Elsalam, S; AbdAllah, M; Cordie, A; El-Akel, W; El-Badrawy, A; El-Bendary, M; El-Shazly, M; Elalfy, H; Elbaz, T; Elegezy, M; Elhadidy, T; Esmat, G; Essam, M; Farid, K; Neamatallah, M; Salama, M | 1 |
1 review(s) available for sofosbuvir and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment.
Topics: COVID-19; GRADE Approach; Humans; Imidazoles; Sofosbuvir | 2022 |
9 trial(s) available for sofosbuvir and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).
Topics: Adult; Antiviral Agents; Carbamates; COVID-19; Humans; Imidazoles; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2022 |
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Topics: Antiviral Agents; Carbamates; COVID-19; Humans; Imidazoles; Nitro Compounds; Pyrrolidines; SARS-CoV-2; Sofosbuvir; South Africa; Thiazoles; Treatment Outcome; Valine | 2022 |
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment.
Topics: COVID-19; GRADE Approach; Humans; Imidazoles; Sofosbuvir | 2022 |
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Hospitalization; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Patient Admission; Pneumonia, Viral; Pyrrolidines; SARS-CoV-2; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2020 |
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Topics: Adult; Ambulatory Care; Antimalarials; Antiviral Agents; Carbamates; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
Topics: Adult; Antiviral Agents; Carbamates; COVID-19; Heterocyclic Compounds, 4 or More Rings; Humans; Iran; Pandemics; Prospective Studies; SARS-CoV-2; Sofosbuvir; Standard of Care; Treatment Outcome | 2021 |
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.
Topics: Antiviral Agents; Carbamates; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Humans; Imidazoles; Length of Stay; Prospective Studies; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2022 |
16 other study(ies) available for sofosbuvir and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units.
Topics: Benzimidazoles; COVID-19; Fluorenes; Humans; Reproducibility of Results; SARS-CoV-2; Sofosbuvir; Spectrophotometry | 2022 |
Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir.
Topics: Antiviral Agents; COVID-19; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; SARS-CoV-2; Simeprevir; Sofosbuvir | 2022 |
RP-HPLC Method Development, Validation, and Drug Repurposing of Sofosbuvir Pharmaceutical Dosage Form: A Multidimensional Study.
Topics: Animals; Chromatography, High Pressure Liquid; COVID-19; Drug Repositioning; Molecular Docking Simulation; Pharmaceutical Preparations; Reproducibility of Results; SARS-CoV-2; Sofosbuvir | 2022 |
Effects of the 5'-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2.
Topics: Antiviral Agents; COVID-19; Cytidine; Escherichia coli; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Vidarabine | 2022 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Catalytic Domain; Computational Biology; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Guanosine Monophosphate; Guanosine Triphosphate; Humans; Molecular Docking Simulation; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Ribavirin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Sofosbuvir; Thermodynamics; Uridine Triphosphate; Viral Proteins | 2020 |
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Heterocyclic Compounds, 4 or More Rings; Humans; Iran; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir | 2020 |
Sofosbuvir as a potential option for the treatment of COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir | 2020 |
Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; DNA-Directed DNA Polymerase; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sofosbuvir; Viral Proteins | 2020 |
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
Topics: Antiviral Agents; Base Sequence; Betacoronavirus; Catalytic Domain; Computer Simulation; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Humans; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Protein Binding; Protein Structure, Tertiary; RNA-Dependent RNA Polymerase; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Sofosbuvir; Viral Nonstructural Proteins | 2020 |
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dideoxynucleosides; Humans; Pandemics; Pneumonia, Viral; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir; Viral Nonstructural Proteins | 2020 |
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibody Reactions; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Eflornithine; Humans; Hydrophobic and Hydrophilic Interactions; Ivermectin; L-Lactate Dehydrogenase; Models, Molecular; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Proline; Protein Binding; Protein Conformation; Protein Interaction Mapping; Receptors, Glycine; Saposins; SARS-CoV-2; Sofosbuvir; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship | 2020 |
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; Drug Discovery; Drug Repositioning; Exonucleases; Hepacivirus; Hepatitis C; Humans; Pandemics; Pneumonia, Viral; Prodrugs; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2020 |
Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Dideoxynucleotides; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; Humans; Pandemics; Pneumonia, Viral; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir; Thymine Nucleotides; Zidovudine | 2020 |
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Chromosomes, Artificial, Bacterial; COVID-19; COVID-19 Drug Treatment; HEK293 Cells; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Replicon; RNA-Binding Proteins; SARS-CoV-2; Sofosbuvir; Vero Cells; Virus Replication | 2021 |
Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.
Topics: Antiviral Agents; Carbamates; China; COVID-19; Humans; Imidazoles; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Valine | 2021 |
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Topics: Animals; Antiviral Agents; Carbamates; Chlorocebus aethiops; COVID-19; Humans; Imidazoles; Pharmaceutical Preparations; Pyrrolidines; RNA, Viral; SARS-CoV-2; Sofosbuvir; Valine; Vero Cells | 2021 |